Compare Moderna, Inc. (MRNA) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Wheaton Precious Metals Corp — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Wheaton Precious Metals Corp trades at $103.33 (market cap $46.54B). The key difference: Wheaton Precious Metals Corp is the larger of the two by market cap, and Wheaton Precious Metals Corp pays a 0.75% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | WPM | |
|---|---|---|
Market Cap | $23.60B | $46.54B |
Sector | Health | Basic Materials |
52-Week High | $81.80 | $165.72 |
52-Week Low | $22.36 | $91.00 |
Enterprise Value | $19.70B | $44.39B |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Wheaton Precious Metals (WPM) trades at $109.96, up 5.55% today, with a bearish technical signal but strong fundamentals. The company reported record revenue of $2.31B in 2025, net income of $1.47B, and has beaten earnings estimates for three consecutive quarters. Operating cash flow surged to $1.90B in 2025, supporting a positive outlook.
WPM offers growth potential with an 80% analyst buy rating and a consensus price target of $161.75, implying significant upside. Risks include exposure to precious metal price volatility and a high P/E ratio of 26.14. The stock's current discount to target presents a buying opportunity for long-term investors, contingent on stable metal prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
